NATUS MEDICAL INC's gross profit margin for the third quarter of its fiscal year 2014 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. NATUS MEDICAL INC has strong liquidity. Currently, the Quick Ratio is 1.98 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 14.93% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY14||Q3 FY13|
|Net Sales ($mil)||89.88||85.39|
|Net Income ($mil)||7.79||6.29|
|Balance Sheet||Q3 FY14||Q3 FY13|
|Cash & Equiv. ($mil)||57.81||44.19|
|Total Assets ($mil)||414.97||415.77|
|Total Debt ($mil)||8.0||48.06|
|Profitability||Q3 FY14||Q3 FY13|
|Gross Profit Margin||64.78||63.91|
|Return on Assets||7.44||4.51|
|Return on Equity||9.31||6.49|
|Debt||Q3 FY14||Q3 FY13|
|Share Data||Q3 FY14||Q3 FY13|
|Shares outstanding (mil)||32.21||30.88|
|Div / share||0.0||0.0|
|Book value / share||10.3||9.35|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||237498.0||284034.0|
BUY. NATUS MEDICAL INC's P/E ratio indicates a discount compared to an average of 41.01 for the Health Care Equipment & Supplies industry and a significant premium compared to the S&P 500 average of 19.41. To use another comparison, its price-to-book ratio of 3.59 indicates a premium versus the S&P 500 average of 2.74 and a discount versus the industry average of 5.04. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, NATUS MEDICAL INC proves to trade at a discount to investment alternatives within the industry.
|BABY 38.57||Peers 41.01||BABY 24.18||Peers 30.45|
Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation.
BABY is trading at a valuation on par with its peers.
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
BABY is trading at a discount to its peers.
|BABY 26.08||Peers 26.32||BABY 0.56||Peers 1.42|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
BABY is trading at a premium to its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
BABY trades at a significant discount to its peers.
|BABY 3.59||Peers 5.04||BABY 57.37||Peers 22.55|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BABY is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
BABY is expected to have an earnings growth rate that significantly exceeds its peers.
|BABY 3.38||Peers 7.01||BABY 2.37||Peers 7.56|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BABY is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
BABY significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV